Clinical trial · Observational
Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab
Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients
NCT00491140CI-TRIAL-00001706completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to identify molecular features predicting response or resistance to cetuximab
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gene mutations analysis and FISH | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observation
- description
- Colorectal cancer patients
- interventionNames
- Genetic: Gene mutations analysis and FISH
Primary outcomes (1)
- measure
- Association of different biomarkers with Cetuximab sensitivity
- timeFrame
- Assessment every two months
Secondary outcomes (1)
- measure
- Association of different biomarkers with time to progression and survival
- timeFrame
- At the end of the study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of colorectal cancer with available tumor tissue and clinical data; presence of at least one measurable lesion. Exclusion Criteria: * Less than 3 weeks after completion of previous radiotherapy
References
Publications (1)
- BACKGROUNDChung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27. PMID 15677699